OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Multifunctional NK Cell–Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release
Katja Klausz, Lukas Pekar, Ammelie Svea Boje, et al.
The Journal of Immunology (2022) Vol. 209, Iss. 9, pp. 1724-1735
Open Access | Times Cited: 26
Katja Klausz, Lukas Pekar, Ammelie Svea Boje, et al.
The Journal of Immunology (2022) Vol. 209, Iss. 9, pp. 1724-1735
Open Access | Times Cited: 26
Showing 1-25 of 26 citing articles:
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 135
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 135
Development of NK cell-based cancer immunotherapies through receptor engineering
Audrey Page, Nicolas Chuvin, Jenny Valladeau‐Guilemond, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 4, pp. 315-331
Open Access | Times Cited: 68
Audrey Page, Nicolas Chuvin, Jenny Valladeau‐Guilemond, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 4, pp. 315-331
Open Access | Times Cited: 68
Britta Lipinski, Paul Arras, Lukas Pekar, et al.
Protein Science (2023) Vol. 32, Iss. 3
Open Access | Times Cited: 18
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
Ammelie Svea Boje, Lukas Pekar, Katharina Koep, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 8
Ammelie Svea Boje, Lukas Pekar, Katharina Koep, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 8
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition
Britta Lipinski, Laura Unmuth, Paul Arras, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Britta Lipinski, Laura Unmuth, Paul Arras, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells
Sebastian Lutz, Katja Klausz, Anca-Maria Albici, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Sebastian Lutz, Katja Klausz, Anca-Maria Albici, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study
Paul Arras, Han Byul Yoo, Lukas Pekar, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 10
Paul Arras, Han Byul Yoo, Lukas Pekar, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 10
Natural killer cell engagers for cancer immunotherapy
Shahryar Khoshtinat Nikkhoi, Geng Li, Arash Hatefi
Frontiers in Oncology (2025) Vol. 14
Open Access
Shahryar Khoshtinat Nikkhoi, Geng Li, Arash Hatefi
Frontiers in Oncology (2025) Vol. 14
Open Access
Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications
Bo Gao, Yan Lu, Xingyue Lai, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Bo Gao, Yan Lu, Xingyue Lai, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization
Paul Arras, Han Byul Yoo, Lukas Pekar, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Paul Arras, Han Byul Yoo, Lukas Pekar, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 9
On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality
Monica L. Fernández‐Quintero, Enrico Guarnera, Djordje Müsil, et al.
Protein Science (2024) Vol. 33, Iss. 11
Open Access | Times Cited: 3
Monica L. Fernández‐Quintero, Enrico Guarnera, Djordje Müsil, et al.
Protein Science (2024) Vol. 33, Iss. 11
Open Access | Times Cited: 3
Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy
Hong Zhang, Qun Wang, Sireesha Yalavarthi, et al.
Cancer Treatment and Research Communications (2024) Vol. 39, pp. 100805-100805
Open Access | Times Cited: 2
Hong Zhang, Qun Wang, Sireesha Yalavarthi, et al.
Cancer Treatment and Research Communications (2024) Vol. 39, pp. 100805-100805
Open Access | Times Cited: 2
Nature Killer Cell for Solid Tumors: Current obstacles and prospective remedies in NK cell therapy and beyond
Jia‐Hao Tao, Jun Zhang, Huashun Li, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 205, pp. 104553-104553
Closed Access | Times Cited: 2
Jia‐Hao Tao, Jun Zhang, Huashun Li, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 205, pp. 104553-104553
Closed Access | Times Cited: 2
Killer instincts: natural killer cells as multifactorial cancer immunotherapy
Sarah Nersesian, Emily B. Carter, Stacey N. Lee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Sarah Nersesian, Emily B. Carter, Stacey N. Lee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy
Stefania Douka, Vasilis Papamoschou, Monica Raimo, et al.
Pharmaceutics (2024) Vol. 16, Iss. 9, pp. 1143-1143
Open Access | Times Cited: 1
Stefania Douka, Vasilis Papamoschou, Monica Raimo, et al.
Pharmaceutics (2024) Vol. 16, Iss. 9, pp. 1143-1143
Open Access | Times Cited: 1
The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer
Amitabh Gaur, Narendra Chirmule
(2024), pp. 1209-1251
Closed Access | Times Cited: 1
Amitabh Gaur, Narendra Chirmule
(2024), pp. 1209-1251
Closed Access | Times Cited: 1
Discovery of potent allosteric antibodies inhibiting EGFR
Léxane Fournier, Lukas Pekar, Birgitta Leuthner, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Léxane Fournier, Lukas Pekar, Birgitta Leuthner, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Allosteric antibodies: a novel paradigm in drug discovery
Léxane Fournier, Enrico Guarnera, Harald Kolmar, et al.
Trends in Pharmacological Sciences (2024)
Open Access | Times Cited: 1
Léxane Fournier, Enrico Guarnera, Harald Kolmar, et al.
Trends in Pharmacological Sciences (2024)
Open Access | Times Cited: 1
Role of B7 family members in glioma: Promising new targets for tumor immunotherapy
Yan Wang, Mengxi Li, Gang Wang, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 3
Yan Wang, Mengxi Li, Gang Wang, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 3
The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer
Amitabh Gaur, Narendra Chirmule
(2023), pp. 1-43
Closed Access | Times Cited: 2
Amitabh Gaur, Narendra Chirmule
(2023), pp. 1-43
Closed Access | Times Cited: 2
Altered NCR3 Splice Variants May Result in Deficient NK Cell Function in Renal Cell Carcinoma Patients
XUELEI WANG, Liqun Huang, Xiaofei Wen, et al.
In Vivo (2023) Vol. 38, Iss. 1, pp. 174-183
Open Access | Times Cited: 2
XUELEI WANG, Liqun Huang, Xiaofei Wen, et al.
In Vivo (2023) Vol. 38, Iss. 1, pp. 174-183
Open Access | Times Cited: 2
Exploring structured molecular landscape from single-cell multi-omics data by an explainable multimodal model
Hui Tang, J.M. Zhong, Xiangtian Yu, et al.
iScience (2024) Vol. 27, Iss. 12, pp. 111131-111131
Open Access
Hui Tang, J.M. Zhong, Xiangtian Yu, et al.
iScience (2024) Vol. 27, Iss. 12, pp. 111131-111131
Open Access
Construction of Semisynthetic Shark vNAR Yeast Surface Display Antibody Libraries
Harald Kolmar, Julius Grzeschik, Doreen Könning, et al.
Methods in molecular biology (2023), pp. 227-243
Closed Access | Times Cited: 1
Harald Kolmar, Julius Grzeschik, Doreen Könning, et al.
Methods in molecular biology (2023), pp. 227-243
Closed Access | Times Cited: 1
Enhancing NK cell-mediated tumor killing of B7-H6 positive cells with bispecific antibodies targeting allosteric sites of NKp30
Léxane Fournier, Paul Arras, Lukas Pekar, et al.
Deleted Journal (2024) Vol. 33, Iss. 1, pp. 200917-200917
Closed Access
Léxane Fournier, Paul Arras, Lukas Pekar, et al.
Deleted Journal (2024) Vol. 33, Iss. 1, pp. 200917-200917
Closed Access
10th antibody industrial symposium: new developments in antibody and adoptive cell therapies
Ana Antunes, Luís Álvarez-Vallina, Federico Bertoglio, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access
Ana Antunes, Luís Álvarez-Vallina, Federico Bertoglio, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access
